The Gauteng health department has surpassed its monthly target for distributing Lenacapavir, a long-acting HIV prevention medication, with over 6,130 eligible individuals initiated on the drug between June 8 and the end of the month.This achievement represents 131% of the set target of 4,672 initiations.

Lenacapavir is being rolled out in phases to provide an additional HIV prevention option for high-risk populations, supporting South Africa’s goal of ending AIDS as a public health threat by 2030.The medicine is now available at 133 public clinics across Gauteng, with adequate stock levels maintained.Tshwane recorded the highest number of initiations (2,216), followed by Johannesburg (1,981) and Ekurhuleni (1,435).

Health officials emphasized that while Lenacapavir is a critical tool, it does not protect against other sexually transmitted infections or unintended pregnancies.They urged continued use of condoms, regular STI screenings, and access to sexual and reproductive health services.

The department also highlighted the importance of expanding HIV prevention services to high-risk communities, with over 15,000 injectable and oral packs remaining in stock.A second consignment of 9,830 packs was delivered to ensure uninterrupted access.

The successful rollout is credited to healthcare workers and programme teams, with the department reaffirming its commitment to comprehensive HIV prevention strategies.